Journal of Clinical Oncology
Articles in this Issue
Cadonilimab combined with lenvatinib for neoadjuvant therapy in early-stage renal cell carcinoma with indications for partial nephrectomy but high surgical risk: A prospective single-arm phase II clinical trial.
530 Background: Partial nephrectomy is the standard treatment for early-stage renal cell carcinoma; however, in some patients, although the tumor is early...
Paclitaxel, ifosfamide, cisplatin (TIP) in patients with advanced urethral adenocarcinoma: A single center, retrospective analysis.
656 Background: Urethral adenocarcinoma (UA) is a very rare subtype of cancers arising in urethra, which is known for female predominance and poor prognos...
NGS-based molecular panel analysis of metastatic prostate cancer for daily routine: How often do we detect druggable mutations?
203 Background: Guidelines recommend molecular analysis to identify druggable mutations after failure of the first-line systemic therapy for metastatic pr...
Site-specific disease progression in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab or axitinib-based immunotargeted combinations.
478 Background: Data on site-specific progression patterns in metastatic renal cell carcinoma (mRCC) treated with immuno-oncology agents are limited. This...
Optyx study: Clinical characteristics and preferences for initiating relugolix in a cohort of US patients in real-world care settings.
67 Background: Relugolix is the only oral androgen deprivation therapy indicated for advanced prostate cancer (PC). The OPTYX study is the first prospecti...
First-line therapies analysis in advanced/metastatic urothelial carcinoma: Prognostic insights with propensity score analysis and RNA-seq.
713 Background: The combination of antibody-drug conjugates (ADCs) and immunotherapy has great prospects for first-line treatment of advanced urothelial c...
Evaluating survival in aggressive variant prostate cancer patients undergoing PSMA radioligand therapy.
259 Background: Aggressive variant prostate cancer (AVPC) is a subtype of metastatic castrate-resistant prostate cancer (mCRPC) characterized by several h...
Homologous recombination deficiency signature (HRDsig+) and the genomic landscape of clinically advanced prostate carcinoma (CAPC).
196 Background: CAPC is very challenging with significant need for improvement in systemic therapy, including for patients (pts) with incurable disease. R...
A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy.
868 Background: Upper tract urothelial carcinoma (UTUC) presents distinct clinicopathological, molecular features, and biological behaviors compared to ur...
Final oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer.
394 Background: High-risk prostate cancer (PCa) patients have a high risk of biochemical recurrence (BCR) and metastatic progression following local thera...
Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results.
150 Background: Treatment of a BCR typically starts with androgen-deprivation therapy (ADT), which is limited by treatment-emergent adverse events (TEAEs)...
Machine learning model integrating CT radiomics and circulating microRNAs to predict residual disease histology in metastatic non-seminoma testicular cancer (mNSTC).
647 Background: The primary treatment of most mNSTC is chemotherapy followed by surgery if the residual disease (RD) is >1 cm. However, conventional im...
Evaluation of MIR-371A-3P for clinical implementation in a CLIA-certified laboratory.
648 Background: MicroRNAs (mi-RNAs) have emerged as promising biomarkers for the detection of viable germ cell tumors (GCT). Our previous work in a resear...
Androgen suppression with abiraterone acetate, leuprolide, PARP inhibition, and stereotactic body radiotherapy (ASCLEPIuS) in high-risk and node positive prostate cancer (PCa): Phase I multicenter results.
387 Background: Level 1 evidence supports treatment of high-risk and node positive PCa using 4-9 weeks of radiotherapy (RT) combined with 18-36 months of...
The impact of pelvic radiotherapy on hematological outcomes in pediatric genitourinary rhabdomyosarcoma.
379 Background: Hematological toxicities are common with radiation therapy (RT), particularly pelvic RT, which affects nearly 50% of total body hematopoie...
Time burden and healthcare costs associated with docetaxel in patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating an androgen receptor pathway inhibitor (ARPI) –based regimen.
58 Background: Prior to ARPIs, chemotherapy was used to treat mCSPC. Recently, intensifying mCSPC treatment with a triplet combination of chemotherapy, AR...
Validation of a 15-gene prognostic signature in metastatic clear cell renal cell carcinoma.
578 Background: Our group previously developed and validated a 15-gene prognostic signature (15G score) in localized clear cell renal cell carcinoma (ccRC...
Molecular evolution of HRR gene alterations in metastatic prostate cancer: A ctDNA-based study.
255 Background: Homologous recombination repair (HRR) genes, including DNA repair genes, are increasingly recognized for impacting treatment resistance an...
Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate Cancer.
65 Background: Intensified androgen deprivation therapy (ADT) with an androgen receptor pathway inhibitor (ARPI) and/or docetaxel has led to improved outc...
Differences in health-related quality of life between rural and urban bladder cancer patients following radical cystectomy.
766 Background: Bladder cancer (BC) patients from rural areas (RA) may have more difficult access to health care with potentially detrimental impact on on...
Comprehensive modalities of kidney-sparing treatment in a carefully selected cohort of localized high-risk upper tract urothelial carcinoma: A potential paradigm shift.
794 Background: This study aims to assess the efficacy and safety of comprehensive modalities of kidney-sparing treatment in a carefully selected cohort o...
Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.
502 Background: Deferred cytoreductive nephrectomy (dCN) is an emerging, strategy in the management of metastatic renal cell carcinoma (mRCC), applied sel...
Assessing the impact of PTEN loss on outcomes in high-/very high-risk, advanced hormone-sensitive prostate cancer patients: Institutional retrospective study.
260 Background: Inactivation of tumor suppressor gene, PTEN (Phosphatase and tensin homolog) by deletion or mutation occurs in between 15-20% of localized...
Prognostic impact of first-line (1L) chemotherapy cycles in patients with metastatic urothelial carcinoma receiving avelumab 1L maintenance.
725 Background: First-line chemotherapy with 4-6 cycles followed by avelumab 1L maintenance therapy is the standard of care in patients with metastatic ur...
Identification of potential immune evasion mechanisms in aggressive small renal cell carcinomas through single-cell and bulk RNA sequencing.
574 Background: Small renal cell carcinoma (RCC) is generally nonaggressive but in some cases, small RCCs exhibit distant metastasis. The biology and biom...